Combining oral ketoconazole with other systemic antifungals is generally discouraged because of overlapping toxicity, especially hepatotoxicity. If combination therapy is considered, it must be orchestrated by a specialist who will monitor liver function closely.
Some herbal products, such as St John’s wort, induce CYP3A4 and can lower ketoconazole levels, reducing efficacy. Conversely, supplements containing grapefruit or its juice can inhibit CYP3A4, potentially raising ketamine concentrations and increasing toxicity risk. Inform your pharmacist of all supplements you take.
Ketoconazole’s elimination half-life is about 8 hours; however, metabolites may persist longer. Typically, the drug is cleared within 2-3 days after the last dose in individuals with normal liver function.
Yes, provided you carry the medication in its original packaging with a copy of the prescription. Some countries may have restrictions on importing antifungal agents, so check the destination’s customs regulations before travel.
Oral ketoconazole is not associated with hair loss; in fact, topical ketoconazole shampoo is sometimes used for scalp conditions. Systemic therapy may affect steroid synthesis, which, in rare cases, could influence hair follicles indirectly, but this is not a common side effect.
If you remember a missed dose within 12 hours, take it as soon as possible. If it is closer to the time of your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Doubling the dose is not recommended.
No specific diet is required, but limiting alcohol consumption is prudent because both alcohol and ketoconazole can stress the liver. High-fat meals may increase absorption, but this effect is modest and does not necessitate timing adjustments.
Oral Nizoral tablets deliver systemic antifungal activity, treating deep-seated infections throughout the body. Topical shampoos act locally on the scalp and are primarily used for dandruff or seborrheic dermatitis; they do not achieve significant blood concentrations.
A liver biopsy is not required in routine practice. Baseline liver function tests (ALT, AST, bilirubin) are sufficient to assess hepatic health before initiating therapy.
Ketoconazole may be employed for opportunistic fungal infections in HIV-positive patients when first-line agents are contraindicated or unavailable. However, clinicians must be vigilant about drug-drug interactions with antiretroviral therapy and monitor liver function closely.
Nizoral (Ketoconazole) - Generic Medication Overview
Nizoral is a brand-name oral tablet that contains the antifungal agent ketoconazole, available in a 200 mg tablet form. Ketoconazole belongs to the antifungal class of medications and is prescribed for systemic fungal infections when alternative agents are unsuitable. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) classifies Nizoral as a prescription-only medicine (POM). The tablet is marketed by various pharmaceutical companies, but the active ingredient and its therapeutic properties are consistent across brands.
Ketoconazole exerts its antifungal effect by inhibiting the fungal enzyme lanosterol 14α-demethylase, a key component of the sterol synthesis pathway. This enzyme is essential for converting lanosterol to ergosterol, the primary sterol that maintains fungal cell membrane integrity. By blocking ergosterol production, ketoconazole disrupts membrane structure, leading to increased permeability and ultimately fungal cell death.
The drug is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring 1-2 hours after ingestion. Ketoconazole is extensively metabolised in the liver, primarily via the cytochrome P450 3A4 (CYP3A4) isoenzyme, and its metabolites are excreted in both urine and feces. The average elimination half-life is approximately 8 hours, allowing once-daily dosing in most therapeutic regimens.
In the UK, oral ketoconazole 200 mg tablets are approved for the treatment of certain systemic mycoses where first-line agents are contraindicated, ineffective, or unavailable. Indications include:
These approvals are based on clinical experience and limited randomized trials, and they are reflected in the Summary of Product Characteristics (SmPC) endorsed by the MHRA.
Evidence from peer-reviewed studies has explored ketoconazole for conditions such as:
When used off-label, ketoconazole must be prescribed under the direct supervision of an endocrinologist or dermatologist, and patients should be informed of the lack of regulatory approval for these indications.
Absolute Contraindications
Relative Contraindications
Special Populations
Major Interactions
Moderate Interactions
General Advice
Patients should disclose all prescription, over-the-counter, herbal, and dietary supplements before initiating Nizoral.
If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double-dose.
Signs may include severe nausea, vomiting, abdominal pain, and hepatic dysfunction. Seek immediate medical attention; gastric lavage and activated charcoal may be considered if presentation is early. There is no specific antidote; treatment is supportive.
Ketoconazole does not usually require tapering. However, abrupt cessation after prolonged therapy may unmask adrenal insufficiency in rare cases; patients should be evaluated for cortisol levels if clinically indicated.
Patients should contact their healthcare provider promptly if they notice jaundice, dark urine, persistent nausea, or unexplained fatigue.
This article provides educational information about Nizoral (ketoconazole) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
